fda glp-1 warning letters news Beyond the Headlines: to Compounders FDA Warns 30 Telehealth Companies

India Demonstrates Strong Market Potential with Rising Obesity Prevalence Revenue from obesity GLP-1 treatment in India is expanding at a CAGR of 28.4%, supported by increasing obesity rates in metropolitan areas and growing awareness of cardiovascular risk factors

Neither GLP-1 agents nor naltrexone are FDA-approved specifically as a combination therapy for weight management

Before I get into the specific medications, I want to introduce a term that is essential to understanding them: incretin

Accepted payment methods include MasterCard, Visa, American Express, and Discover

On one hand, social media might suggest these drugs are a "miracle" with no downsides

It can be prescribed off-label to promote weight loss in some cases